---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-202285"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:54:31.275579+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AlloVir Q2 net loss $45.3M; cash $246.5M; three Phase 3 trials on track for H2 2024 data

## Summary
- Net loss of $45.3M ($0.48 per share) vs $44.6M ($0.69) in Q2 2022.
- Cash, equivalents, and short-term investments $246.5M as of June 30, 2023.
- Closed public offering with gross proceeds ~$75M, extending cash runway into 2025.
- Three Phase 3 registrational trials of posoleucel in allo-HCT patients; data expected H2 2024.
- FY 2023 operating expense guidance $150M-$170M excluding non-cash items.

## SEC filing metadata
- accession: 0001193125-23-202285
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312523202285/0001193125-23-202285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312523202285/d533010d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-202285
- JSON: https://secwatch.observer/filing/0001193125-23-202285.json
- Plain text: https://secwatch.observer/filing/0001193125-23-202285.txt

## Key facts
- Earnings Releases
  Kalaris Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income net loss was $45.3 million or $0.48 per share, EPS $0.48 per share. Guidance reaffirmed.
  - Period: the quarter ended June 30, 2023
  - Net income: net loss was $45.3 million or $0.48 per share
  - EPS: $0.48 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: For the quarter ended June 30, 2023, net loss was $45.3 million or $0.48 per share compared with a net loss of $44.6 million or $0.69 per share for the quarter ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312523202285/0001193125-23-202285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.